Long-term survival after radical resection for pancreatic head and ampullary cancer: A potential role for the EGF-R

Digestive Surgery

Volumn 24, Issue 1, 2007, Pages 38-45

  Smeenk, H G ^a   Erdmann, J ^a   Van Dekken, H ^a   Van Marion, R ^a   Hop, W C J ^a   Jeekel, J ^a   Van Eijck, C H J ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Ampullary cancer; C myc; Epithelial growth factor receptor; Pancreatic head cancer; Prognostic factors; Survival, ampullary pancreatic head cancers; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; CHROMOGRANIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MYC PROTEIN; PROGESTERONE RECEPTOR; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; ARTICLE; CANCER INVASION; CANCER PAIN; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NERVE TUMOR; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT OUTCOME;

AMPULLA OF VATER; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247187406     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100917     Document Type: Article

References (40)

1. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54:385-387.
2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-488.
3. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-782; discussion 782-774.
4. van Oost FJ, Luiten EJ, van de Poll-Franse LV, Coebergh JW, van den Eijnden-van Raaij AJ: Outcome of surgical treatment of pancreatic, peri-ampullary and ampullary cancer diagnosed in the south of The Netherlands: a cancer registry based study. Eur J Surg Oncol 2006;32:548-552.
5. Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372-1381.
6. Vogel I, Kalthoff H, Henne-Bruns D, Kremer B: Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma. Pancreatology 2002;2:79-88.
7. Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry S, Fagot H: Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg 1994;81:102-107.
8. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC: Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993;217:144-148.
9. Appelqvist P, Viren M, Minkkinen J, Kajanti M, Kostiainen S, Rissanen P: Operative finding, treatment, and prognosis of carcinoma of the pancreas: an analysis of 267 cases. J Surg Oncol 1983;23:143-150.
10. Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72; discussion 72-73.
11. Nix GA, Dubbelman C, Wilson JH, Schutte HE, Jeekel J, Postema RR: Prognostic implications of tumor diameter in carcinoma of the head of the pancreas. Cancer 1991;67:529-535.
12. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Büchler MW: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-768.
13. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
14. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH, Argani P: Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 2004;35:357-366.
15. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF: Hypophosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci USA 1997;94:10699-10704.
16. Medema RH, Herrera RE, Lam F, Weinberg RA: Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995;92:6289-6293.
17. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP: Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005;41:2213-2236.
18. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U: c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 2002;15:462-469.
19. Büchler P, Reber HA, Eibl G, Roth MA, Büchler MW, Friess H, Isacoff WH, Hines OJ: Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol 2005;27:1125-1130.
20. Li J, Kleeff J, Giese N, Büchler MW, Korc M, Friess H: Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 2004;25:203-210.
21. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-1734.
22. Sobin LH, Wittekind C (eds): TNM Classification of Malignant Tumors, ed 6. New York, Wiley, 2002.
23. Ridder GJ, Klempnauer J: Back pain in patients with ductal pancreatic cancer: its impact on resectability and prognosis after resection. Scand J Gastroenterol 1995;30:1216-1220.
24. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M: Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas 2001;22:279-284.
25. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
26. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A: Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232-1237.
27. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ: A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-628; discussion 628-630.
28. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. 2. Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355-366; discussion 366-368.
29. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508-517.
30. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S: Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10:511-518.
31. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJ: Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992;7:1503-1511.
32. Howe JR, Conlon KC: The molecular genetics of pancreatic cancer. Surg Oncol 1997;6:1-18.
33. Real FX: A 'catastrophic hypothesis' for pancreas cancer progression. Gastroenterology 2003;124:1958-1964.
34. Tezel E, Nagasaka T, Nomoto S, Sugimoto H, Nakao A: Neuroendocrine-like differentiation in patients with pancreatic carcinoma. Cancer 2000;89:2230-2236.
35. Friess H, Wang L, Zhu Z, Gerber R, Schröder M, Fukuda A, Zimmermann A, Korc M, Büchler MW: Growth factor receptors are differentially expressed in cancers of the papilla of Vater and pancreas. Ann Surg 1999;230:767-774; discussion 774-775.
36. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL: Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg 2006;23:74-79.
37. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356.
38. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, Raphael M, Penault-Llorca F, Breau JL, Fagard R, Khayat D, Wind P: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005;16:102-108.
39. Chan SK, Hill ME, Gullick WJ: The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006;11:3-11.
40. Blackledge G, Averbuch S: Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 2004;90:566-572.